Promotie onderzoek

KNMP stelt wetenschappelijk onderzoek voorop. Hier kunt u de meest recente onderzoeken vinden.
Er zijn4resultaten gevonden
Antistolling

Population-beased research in myelodysplastic syndrome

  • Universiteit Rijksuniversiteit Groningen
  • Promovendus Hanne Rozema
  • Promoters Eric van Roon
  • Co-Promoters Mels Hoogendoorn Robby Kibbelaar
  • Jaar 2018 - 2022
Antistolling

Patient experience with NOAC therapy, a real life population study

  • Universiteit Rijksuniversiteit Groningen
  • Promovendus Darko Mitrovic
  • Promoters Eric van Roon
  • Co-Promoters Nic Veeger Karina Meijer
  • Jaar 2019 - 2024
Antistolling

Optimisation of intramural patient care in the field of anticoagulation

  • Universiteit Rijksuniversiteit Groningen
  • Promovendus Annette van Ojik
  • Promoters Eric van Roon Karina Meijer
  • Co-Promoters Mels Hoogendoorn Nic Veeger
  • Jaar 2018 - 2022
Geneesmiddelregulering

Healthcare professionals’ views on clinical relevance of new medicines in primary care

  • Universiteit Rijksuniversiteit Groningen
  • Promovendus Marloes Dankers
  • Promoters prof. dr. Liset van Dijk prof. dr. Aukje Mantel-Teeuwisse
  • Co-Promoters dr. Marjorie Nelissen
  • Jaar 2019 - 2023

New medicines are evaluated by registration authorities in order to assess their benefit-risk-balance. However, not every new medicine has to have an added therapeutic value compared to already available medicines. The real clinical relevance of new medicine is therefore sometimes unclear. In this research project, we want to investigate the views of healthcare professionals (HCPs) on clinical relevance of new medicines in primary care. We will discuss healthcare professionals’ views on clinical relevance of new COPD and T2DM medicines and also describe the reasons for prescribing new medicines, which is often not in line with guideline recommendations. Finally, we want to investigate how healthcare professionals assess the clinical relevance of medicines that obtained market access in the last years, and to investigate which pharmaceutical gaps (in other words: which diseases cannot be properly treated and would demand new therapies) HCPs identify in their daily practice.Â